Dr. Abdel Aziz Shaheen is aClinical Assistant Professor for theDepartment of Medicinein the Section of Gastroenterology with interests in improving health outcomes of Gastrointestinal and Liver Disease. Prior to this, Dr. Shaheen completed his fellowship at the University of Calgary.
Adrian Di Bisceglie
Dr. Di Bisceglie received his medical degree from the University of Witwatersrand, Johannesburg, South Africa in 1977 and completed his training in Internal Medicine at Baragwanath Hospital, Johannesburg before doing a research fellowship at the National Institutes of Health (NIH) between 1986 and 1988. He went on to become a Senior Investigator, and then chief of the Liver Diseases Section, NIDDK. Dr. Di Bisceglie is board certified in transplant hepatology and his research career has been focused on viral hepatitis and hepatocellular carcinoma. He is the author or co-author of close to 500 original articles, reviews and book chapters and has been principal investigator or co-investigator on multiple NIH grants. He has served on the editorial boards of many journals including Hepatology, Liver Transplantation and as Section Editor, Hepatitis C for UpToDate. He has served on many international and national committees including the Scientific Planning Committee for the Global Hepatitis Summit to be held in Toronto in 2018 and has chaired the American Association for the Study of Liver Diseases (AASLD) Public Policy and Clinical Research Committees.
Dr. Di Bisceglie served on the governing board of AASLD from 2009 to 2015 and was President of that organization in 2014. Dr. Di Bisceglie moved to Saint Louis University School of Medicine as Professor of Internal Medicine and has been on the faculty there since 1994. At Saint Louis University, Dr. Di Bisceglie initially served as Associate Chairman for Education and residency program director (1994-1999). He has served on multiple institutional committees, including the Curriculum Oversight Committee, the Governing Board of Saint Louis University Hospital (1998-2000), and more, recently the Governing Board of the University Medical group. He was appointed as acting chairman of the Department of Internal Medicine in 2006 and then served as chairman through 2017. From 2010 to 2019, he was the holder of the Bander Chair in Internal Medicine. Dr. Di Bisceglie has served as a member on the Blood Products Advisory Committee of the FDA, as an advisor to NIH and to the CDC.
He was a long-time member of the U.S. Hepatitis Panel for the U.S. Japan Cooperative Medical Sciences Program. Dr. Di Bisceglie has received numerous honors and awards, including the Fiterman Foundation Clinical Research in Hepatology or Nutrition Award, the AASLD Distinguished Service Award, and Outstanding St. Louis Scientist Award from the Academy of Science of St. Louis. He currently is PI and Co-PI on several NIH sponsored grants and served as Chair, Steering Committee for the HALT-C Trial group. He has also served on the boards of Saint Louis University Hospital and the 500-physician member University Medical Group of Saint Louis University. Dr. Di Bisceglie has served over many years as a consultant and member of medical or scientific advisory boards to a variety of pharmaceutical and diagnostic companies. He currently serves on the board of ACM Care, a not-for-profit corporation providing health care services to the elderly.
Dr. Singal is an Associate Professor and Clinical Chief of Hepatology at UT Southwestern Medical Center in Dallas, TX. He is an expert in hepatocellular carcinoma (HCC) and serves as the Medical Director of the UT Southwestern Liver Tumor Program. He has obtained independent National Institute of Health (NIH) funding, Department of Defense (DOD) funding, and state-level funding examining the HCC care continuum, ranging from HCC prevention to screening and early detection to treatment and survivorship. Dr. Singal has published over 150 scientific papers regarding HCC screening and treatment. For his work, he has been awarded the David Bruton Professorship in Clinical Cancer Research and Blue Faery Award for Excellence in Liver Cancer Research.
Andrew Aronsohn is an Associate Professor of Medicine in the Center for Liver Diseases at the University of Chicago Medical Center. Dr. Aronsohn is also a faculty member at the MacLean Center for Clinical Medical Ethics at the University of Chicago. Dr. Aronsohn is the co-principal investigator of HepCCATT, an initiative to diagnose, link to care and treat HCV in the Chicago area. This project utilizes telehealth technology to expand HCV management into the primary care setting. Dr. Aronsohn is the co-lead of the AASLD / IDSA HCV guidance writing committee as was a member of National Academies of Medicine committee which wrote “A National Strategy for the Elimination of Hepatitis B and C”. He also has a busy clinical practice, which includes both general and transplant hepatology.
Dr. Vaillant has more than 15 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of Replicor’s NAP technology. He oversees all intellectual property, regulatory, manufacturing and research and development activities at Replicor. He also plays a key role in the design, conduct and oversight of clinical trials and oversees all clinical data analysis. He has authored numerous publications and patents on the use of NAPs in various infectious diseases.
Dr. Anton Skaro joined the Division of General Surgery and Multi-Organ Transplant Program, Department of Surgery, Western University in September as an Associate Professor. Dr. Skaro completed medical school at Western University followed by residency and a PhD at Dalhousie University. He completed a fellowship in Transplantation Surgery at Northwestern University in Illinois after which he joined the Northwestern Department of Surgery as an Assistant Professor. He was promoted to Associate Professor at Northwestern in 2014.
Dr. Skaro’s research in liver transplantation has garnered significant grant funding from the National Institutes of Health (NIH) / National Institute on Aging/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). He has more than 50 publications in the peer-reviewed literature and has presented his research nationally and internationally.
Clinical Research Fellow at the University of Alberta Hospital
Dr. Christopher Rose is currently Associate Professor in the Department of Medicine at the Université de Montréal. He is director of the Neuro-Hepato laboratory which is located at University Hospital Research Center (CRCHUM). Dr. Rose received his PhD (Neuroscience/Biomedical Sciences) from the Université de Montréal in 2000. He continued his research interests in Europe by pursuing post-doctoral studies in Germany (Prof. Kettenmann, Berlin), Spain (Prof. Felipo, Valencia and Prof. Cordoba, Barcelona) and Norway (Dr. Ytrebo, Tromso). In doing so, he was the recipient of 3 prestigious post-doctoral fellowship awards from the Alexander von Humboldt Foundation (Germany), Canadian Institute of Health Research (Canada) and the European Association for the Study of the Liver (Europe). Dr. Rose’s research interests lie within the area of hepatic encephalopathy (HE), a field in which he has been researching for over 25 years.
Dr. Jenne is an associate professor in the department of Microbiology, Immunology and Infectious Diseases and the department of Critical Care Medicine at the University of Calgary and is the Canada Research Chair in Imaging Approaches Towards Studying Infections. The Jenne lab uses the technique of intravital microscopy to study the early innate immune and inflammatory responses to viral and bacterial infections. Intravital microscopy allows us to look directly within the blood vessels and tissues of live animals to “see” interactions between immune cells and pathogens in real-time. Current research projects in the lab include using intravital microscopy to characterize the liver immune response to viral and bacterial infection, the impact of fatty liver disease on host immunity, and the interactions between inflammation and coagulation leading to tissue damage in sepsis.
In addition, Dr. Jenne is the Scientific Director of the Snyder Translational Lab in Critical Care Medicine, a position that allows him to work directly with Clinicians and Researchers on human clinical studies. The Snyder Translational Lab serves to enable and support clinical research within the University of Calgary and Canada as a whole. By providing technical expertise, basic biochemical assay support, advanced multiplexing of biomarkers, novel assay development the Snyder lab has contributed to the publication of numerous basic science and clinical manuscripts in the past four years and has contributed pilot data for a number of grant applications.
Dr. Peretz is a practicing hepatologist at University of Manitoba where he serves as the director of the Manitoba Liver Transplant Program.
Dr. Constantine (Dean) Karvellas is an Associate Professor of Medicine (Critical Care Medicine and Gastroenterology/Hepatology) at the University of Alberta and an Adjunct Professor in the School of Public Health Sciences. He has been an attending intensivist in the E. Garner King General Systems Intensive Care Unit since 2009 and is involved with the Liver Transplant program as a Hepatologist.Dr. Karvellas is a co-investigator in the NIH-funded United States Acute Liver Failure study group (US ALFSG). He is a member of Society of Critical Care Medicine (SCCM) Liver management task force. Dr. Karvellas’ publications reflect his interests in acute liver failure (ALF), acute on chronic liver failure (ACLF), liver transplantation and extracorporeal liver support.
Clinical Research Nurse at Saskatchewan Health Authority
Ellie Barnes is Professor of Hepatology and Experimental Medicine, University of Oxford. She has along-standing interest in hepatotrophic viruses, viral pathogenesis, immunology and vaccine development. More recently she has led early human experimental medicine studies with the aims of developing a prophylactic HCV vaccine, including 2nd generation HCV vaccines based on conserved viral genomes, and constructs that encode genetic adjuvants with the potential for wide applicability in cancer and infectious disease. She is also developing a program in HBV using simian adenoviral vectored vaccines for HBV immunotherapy. Ellie was the Chief Investigator for the UK wide MRC funded consortium STOP-HCV developing stratified medicine to optimize patient clinical outcomes (<a href="http://www.stop-hcv.ox.ac.uk/home">http://www.stop-hcv.ox.ac.uk/home</a>); the consortium has developed new methods for HCV sequencing, identifying drug-resistant subtypes, and is currently supporting stratified medicine studies in Vietnam. The World Health Organization has set a target to achieve elimination of HCV by 2030-but very few countries are likely to achieve this. An effective preventative vaccine would have a major impact on HCV incidence and would represent a major advance towards global HCV control. Progress in the development of new vaccine platforms to induce high magnitude and broad anti-viral immune responses to HCV means that it should be possible to generate effective HCV vaccines. The major hurdles to achieving this are now political and practical issues around the funding and testing of vaccine candidates.
Giada Sebastiani is Associate Professor of Medicine at McGill University and Clinician Scientist at the Research Institute of McGill University Health Centre in Montreal, Canada. She provides clinical services in the Division of Gastroenterology and Hepatology. She received a medical degree and specialized in internal medicine at the University of Padua, Italy. She had training in clinical and basic research at Harvard Medical School (US), University College of London (UK), University of Bordeaux (France) and Lady Davis Institute for Medical Research (Montreal, Canada). Her work focuses on fatty liver disease, liver fibrosis and non-invasive diagnostic tools in liver disease, with a current focus on at-risk populations, including people living with HIV, diabetics, patients with inflammatory bowel diseases and women with polycystic ovary syndrome. She is the author of over 80 articles in peer-reviewed journals (including Hepatology, Journal of Hepatology, Clinical Infectious Diseases, AIDS; h-index=30, total number of citations>3,600), 16 book chapters, 170 conference publications at national and international congresses. She has been invited speaker in 70 international congresses and universities, including European, Asian Pacific, Mexican, Italian and Canadian Associations for the Study of the Liver. She was awarded the prestigious Clinical Research Salary Award from Fonds Recherche Sante Quebec. Other honors include: honorary membership of the Romanian Association for the Study of the Liver; Emerging Stars in Hepatology Award (Asian Pacific Association for the Study of the Liver, 2010); Top 10 cited papers 2006-2008 Award by Journal of Hepatology - European Association for the Study of the Liver. She is funding and steering committee member of the Canadian NASH Network and the sole North American representative in the guidelines of the European AIDS Clinical Society.
Professor Gideon Hirschfield is the Lily and Terry Horner Professor of Autoimmune Liver Disease Research at the Toronto Centre for Liver Disease, Toronto, Canada. He directs the autoimmune liver disease programme and is a Staff Hepatologist at Toronto General Hospital. He divides his time between translational research in autoimmune liver disease, and his clinical, Hepatology/Transplant practice. In keeping with Toronto's extensive clinical liver disease programme, in particular, the cohorts of patients with PBC, PSC and AIH he directs, are some of the largest internationally, resulting in a unique clinical expertise related to their day-to-day management pre- and post-transplant, as well as opportunity to involve patients in translational research projects, and in novel clinical trials of new therapies.”
Dr. Azhari is aResident Physician in Gastroenterology & Hepatology at the University of Calgary.
Gastroenterology and Hepatology Fellow at University of Calgary.
Dr. Jennifer Flemming is a hepatologist and clinician scientist at Queen’s University at the rank of Assistant Professor. She completed Internal Medicine and Gastroenterology training at Queen’s University from 2006-2011. She then completed an advanced fellowship in Clinical Hepatology and received a Master’s Degree in Advanced Clinical Research at the University of California San Francisco from 2011-2013 under the mentorship of Dr. Norah Terrault. Her research program focuses on Health Services and Outcomes research related to cirrhosis and primary liver cancer using the databases holdings at ICES-Queen’s. Her program is currently funded by a Southeastern Ontario Academic Medical Association New Clinician Scientist Award and an American Association for the Study of the Liver (AASLD) Foundation Clinical, Translational and Outcomes Research Award.
Dr. John Law received his Ph.D. in the Department of Cell Biology at the University of Alberta. He continued his post-doctoral training with Dr. Charles Rice at the Rockefeller University in New York City studying the molecular virology of RNA viruses including Hepatitis C virus (HCV). He also has experience in developing methods to identify novel viruses in clinical samples. Currently, he is working as part of a team, led by Drs. Michael Houghton and Lorne Tyrrell, to develop a prophylactic vaccine to prevent HCV infection. His research focuses on characterizing the breadth of vaccine-induced neutralizing antibodies and understanding the mode of protection of these antibodies. His research in the Li Ka Shing Applied Virology Institute in Edmonton is working toward an improved 2nd generation HCV vaccine to prevent global infection in the future.
Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Currently, Dr. Feld is clinician-scientist based at the Toronto General Hospital, Toronto Centre for Liver Disease and the McLaughlin-Rotman Centre for Global Health.
Juan Gonzalez Abraldes
Dr Abraldes graduated from the Unversity of Santiago de Compostela Medical School (Spain) in 1995. He did his GI and hepatology training at the University of Barcelona. He did post-doc research focused in portal hypertension at Yale University. He moved to the University of Alberta in 2013, where his current focus is to study the pathophysiology, diagnosis and treatment of Portal Hypertension.
Dr. Patel received his Bachelor of Medicine degree from the University of Southampton, United Kingdom and completed his clinical fellowships in Internal Medicine and Gastroenterology/Hepatology in Western Australia. He completed a 3-year post-doctoral research fellowship in Clinical and Translational Research in viral hepatitis at Scripps Clinic and Research Foundation, San Diego, CA and Duke Clinical Research Institute, Durham NC. He was on faculty at Duke University 2004-2015 before moving to UHN Toronto in October 2015. His research interests include early phase clinical therapeutic trials for viral hepatitis and NASH fibrosis, and the incorporation of functional genomic tools to develop non-invasive biomarkers of fibrosis progression.
Dr. Pantopoulos is an internationally recognized scientist in the field of iron metabolism. His work has contributed to understanding the mechanisms of intracellular iron sensing by “iron regulatory proteins,” IRP1 and IRP2. His lab has been continuously supported by extramural funds from the Canadian Institutes for Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), the Fonds de la recherche en santé du Quebéc (FRSQ), the Cancer Research Society, the Canadian Liver Foundation, and other agencies. He has received scholarships from the CIHR and FRSQ and he currently holds the prestigious FRSQ Chercheur national award.
Dr. Mamatha Bhat is a staff Hepatologist and clinician-scientist at UHN's Multi Organ Transplant Program and UofT's Division of Gastroenterology. She graduated from medical school at McGill University and completed a residency in Internal Medicine and Gastroenterology at the McGill University Health Centre. She completed an MSc in Experimental Medicine, as part of the Royal College Clinician Investigator Program, followed by a fellowship in Transplant Hepatology at Mayo Clinic in Rochester, Minnesota. She subsequently completed a PhD in Medical Biophysics through a CIHR Fellowship for Health Professionals. She has established a research program that uses a systems biology approach to liver disease and transplantation.
Dr. Khalili is a Professor of Medicine at University of California San Francisco and Chief of Clinical Hepatology at San Francisco General Hospital. Her clinical and translational research program focuses on natural history of viral hepatitis, alcoholic and non-alcoholic fatty liver disease, their associated complications including abnormalities of glucose metabolism, and investigating novel therapies for viral hepatitis and NAFLD. She is the principal investigator of the San Francisco Consortium for the NIH-sponsored Hepatitis B Research Network. Her research program also serves as the platform for mentoring junior investigators in patient-oriented research in liver disease to achieve independence in research careers and she is the Co-Director of the UCSF Clinical and Translational Science Institute Mentor Training Program aimed at building a community of effective mentors in biomedical sciences.
Dr Bilodeau went to medical school at Laval University and completed his residency in Internal Medicine at the Royal Victoria Hospital in McGill and his training in Gastroenterology at Université de Montréal. He underwent a research fellowship on the hepatocyte cell cyle at INSERM U-49 in Rennes, France. Since 1995, he is a physician at the Liver Unit of Hôpital Saint-Luc that is now known as the CHUM in Montreal. Since 2014, he is Professor of Medicine at Université de Montréal. He has been the Director of the National CIHR Research Training Program on Hepatitis C from 2009 to 2014. He is the current president of the Canadian Association for the Study of the Liver. He is the current Chief of the Department of Medicine in CHUM. His research interest are centered focus on the adaptation of the liver to injury and on the anomalies of energy metabolism in the pathogenesis of hepatocellular carcinoma. He runs a post-transplant liver clinic and has been transitioning young adults with a variety of liver conditions between 2005 and 2014.
Dr. Mark Swain is Professor of Medicine and Head of the Division of Gastroenterology and Hepatology at the University of Calgary, and is Section Head for the Section of Gastroenterology for the Calgary Zone of Alberta Health Services. He currently holds the Cal Wenzel Family Foundation Chair in Hepatology. Dr. Swain is a clinician-scientist with a basic science research interest focused on two main areas: (i) deciphering how inflammatory liver diseases cause symptoms such as fatigue, impaired cognition (“brain fog”) and altered mood (depression and anxiety), and (ii) delineating the role of the innate immune system in regulating hepatic inflammation . His clinical interests are focused in the areas of quality improvement and wait time reduction strategies, and his clinical research interests involve studying fatty liver disease (NAFLD), autoimmune liver disease and viral hepatitis.
Dr. Matthew Flick is an Associated Professor in the Department of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill (UNC). Dr. Flick has appointments in the UNC Lineberger Comprehensive Cancer Center, Blood Research Center and the Nutrition and Obesity Research Center. The long-term goal of his research program is to identify and characterize novel mechanisms linking coagulation system factors to the progression of malignant and inflammatory diseases. This program is founded on a long-standing interest in defining the functional relationship between hemostatic system components (e.g., prothrombin, fibrinogen) and the regulation of inflammation. Current projects on obesity seek to define the mechanisms by which pathological coagulation system activity drives metabolic inflammation and the progression of obesity-associated disease sequelae, including Non-alcoholic Fatty Liver Disease (NAFLD). Specifically, the lab is investigating which molecular forms of fibrin(ogen) (ie, soluble monomer, polymer, crosslinked polymer) promote metabolic inflammation in the context of a high fat diet challenge. The cutting-edge obesity research performed in my laboratory takes advantage of novel gene-targeted mice in which fibrin(ogen) is functionally modified, mechanism-based in vitro cell culture analyses, and studies of patient biopsy samples to determine functional relationships between fibrinogen and obesity, metabolic inflammation, and liver disease.
Dr. Bazinet is responsible for the development strategy of the Company, and oversees all operations, including the planning of clinical trials. Previously, Dr. Bazinet worked as assistant professor in the departments of Urology and Oncology at McGill University in Montreal. He did his medical training at Sherbrooke University, his urology training at McGill University after which he did a 3-year fellowship in human tumor immunology and urologic oncology at the Memorial Sloan-Kettering Cancer Center in New York from 1984 to 1987.
Viral Hepatitis Outreach Specialist
Dr. Nadine Kronfli's research focuses on designing, deploying, and evaluating evidence-based models of care that aim to increase engagement along the HIV and hepatitis C virus care cascades for vulnerable populations, with a particular focus on people in prison and asylum seekers. The ultimate goal of her research is to support the development of evidence-based policies to improve population health with an emphasis on controlling and eliminating HIV and hepatitis C.
Dr. Shoukry obtained her Pharmacy degree from Cairo University (1991) and Ph.D. in Immunology from McGill University (2000). Her postdoctoral research has established the essential and complementary roles of CD8 and CD4 T lymphocytes in resolution and protection from HCV infection. Since joining the Université de Montréal and CRCHUM in 2005, she has established a translational research program focused on studying immunity to HCV in a unique cohort of people who inject drugs in collaboration with Dr. Julie Bruneau.
Recently, her research has expanded to studying immunological mechanisms of liver fibrosis progression and development of liver cancer. She has published over 65 articles in high impact journals related to liver immunology and has received multiple awards from the American Liver Foundation, the Canadian Institutes of Health Research (CIHR) and Fonds de recherche du Québec – Santé (FRQS). Since 2015 she has been the Director of the Canadian Network on Hepatitis C (CanHepC), federally funded network with over 100 investigators, trainees and knowledge users working towards establishing a pipeline from research to implementation and to improve the lives of Canadians living with hepatitis C.
Dr. Natasha Chandok is a Hepatologist in Woodbridge and at William Osler Health Centre in Brampton, Ontario. She is also Deputy Editor of Canadian Liver Journal.
Dr. Natasha Martin is an infectious disease economic modeler who develops dynamic transmission models to evaluate the impact and cost-effectiveness of public health interventions. She is currently an Associate Professor in the Division of Global Public Health, Department of Medicine at the University of San Diego and holds an honorary senior lecturer position in the School of Social and Community Medicine, University of Bristol. She is also the co-director of the Biostatistics and Modeling Core of the University of California San Diego Center for AIDS Research (UCSD CFAR). She has worked for 18 years developing mathematical models of disease progression and transmission in both communicable and non-communicable diseases. For the past eight years, her primary research has focused on modeling hepatitis C virus (HCV) and HIV transmission and prevention among high-risk groups such as people who inject drugs (PWID), men who have sex with men, and female sex workers. She is a leading researcher on modeling the impact of HCV treatment as prevention. Additionally, she has experience developing dynamic cost-effectiveness evaluations of case-finding and prevention interventions, and has the only published cost-effectiveness models of HCV case-finding interventions and treatment including both individual and population benefits. She is the principal investigator (PI) of a NIDA-funded R01 using epidemic modeling and cost-effectiveness techniques to optimize HIV and HCV prevention portfolios among people who inject drugs in 108 countries worldwide. Her modeling work informed the WHO guidelines “When to start ART in people living with HIV (2013)”, and her work on the impact and cost-effectiveness of HCV treatment among people who inject drugs informed the WHO guidelines on “Hepatitis C testing, care, and treatment (2013)”. More recently, her modeling work on HCV elimination was used to inform the WHO “Global Health Sector Strategy on Viral Hepatitis 2016-2021”.
Pascal Lapierre is a Research Associate at CHUM
Dr. Metrakos is a Professor of Surgery, Pathology and Anatomy and Cell Biology.His research focuses on liver physiology, pathology and molecular signatures.
Philippe Mathurin is Professor of Hepatology and Head of the research program on liver disease in the Department of Hepatology and Gastroenterology at the University Hospital of Lille, in France. After completing his medical training and achieving his PhD, he undertook a research fellowship in Professor Tsukamoto’s laboratory at the USC School of Medicine in Los Angeles, USA, between 1997 and 1999. He has been associate editor of the Journal of Hepatology. Philippe Mathurin has published more than 250 articles in prominent journals including the New England Journal of Medicine, JAMA, Gastroenterology, Hepatology, Gut and the Journal of Hepatology. His main research interests are alcoholic liver disease, viral hepatitis, non alcoholic fatty liver disease and hepatocellular carcinoma.
Dr. Kumar is a therapeutic endoscopist. She is a member of the Division of Gastroenterology and Hepatology within the Department of Internal Medicine at the University of Calgary. Areas of interest include: application and evaluation of advanced endoscopic techniques including endoscopic ultrasound, deep enteroscopy, endoscopic mucosal resection and endoscopic submucosal dissection in western cohorts.An area of special interest is endoscopic skill acqusition. She also has multiple educational roles at varying levels of medical education. The majority of these research efforts involve collaboration with colleagues at the University of Calgary as well as other centres.
Rachelle is a PhD student who is currently studying the immune environment in the liver. This work focuses both on the impact of chronic liver disease, such as non-alcoholic fatty liver disease (NAFLD) on the host immune response and tissue pathology and on the ability to reprogram this immune environment.
Dr. Honegger is an assistant professor of pediatrics at The Ohio State University and serves as an attending physician in the division of pediatric infectious diseases at Nationwide Children's Hospital and primary investigator in the Center for Vaccines and Immunity at the Abigail Wexner Research Institute. His primary research interests center on cellular immunity to the hepatitis C virus (HCV) in pregnancy and childhood, as well as diagnosis, treatment, and prevention of pediatric HCV infection. He has also served as a site investigator for trials of direct acting antiviral therapies for chronic HCV infection in children.
University of California, San Diego
Dr. Gujar, a veterinarian-turned-scientist, specialises in harnessing the awesome powers of our immune system to target cancers. His research thus far has revealed that we can train our immune system using oncolytic viruses- to not only eradicate the existing cancer cells, but also establish long-term protection against possible relapse. Going forward, he envisions to use oncolytic viruses to promote lifelong cancer free health.
Dr. Simon Ling graduated in medicine from the University of Edinburgh, Scotland and trained in paediatric gastroenterology in Scotland and Toronto. Following his appointment to SickKids and the University of Toronto in 2003, Dr Ling has served as Head of the Division of Gastroenterology, Hepatology and Nutrition since 2015 and previously as Director of the Paediatric Gastroenterology Training Program. He received the Department of Paediatrics’ Richard Rowe Award for Clinical Excellence in Paediatric Medical Care in 2013. Dr. Ling’s subspecialty interest is paediatric liver disease and he also maintains a broad expertise in paediatric gastroenterology and endoscopy. His clinical research activities aim to improve our understanding of the progression of chronic liver disease and its complications in children, focusing on children with chronic viral hepatitis B and C, children with cystic fibrosis liver disease (CFLD), and children at risk of variceal bleeding. He collaborates in the Hepatitis B Research Network (HBRN), CanHepC, and the CFLD Research Network.
Dr. Sofia Bartlett is a postdoctoral research fellow in the clinical prevention services division at the British Columbia Centre for Disease Control and Department of Pathology and Laboratory Medicine at the University of British Columbia. She obtained her Doctorate degree (PhD) in Molecular Epidemiology at the Kirby Institute, University of New South Wales in Sydney, Australia. Her research focusses on improving the health of marginalised populations, such as people who inject drugs and people living with hepatitis C infection. Sofia’s research utilizes a multidisciplinary approach, combining molecular genetics, bioinformatics and clinical epidemiology, and she is currently working on applying syndemic theory to understand factors related to gaps in the care cascade for hepatitis C infection in British Columbia.
Dr. Stephanie R. Wilson graduated in Medicine with distinction from the University of Alberta. Following her subsequent internship at the Foothills Hospital at the University of Calgary, she moved to the University of Toronto where she completed her residency in Radiology.
Dr Wilson’s medical career has a strong foothold in Toronto, where she served as the Chief of the Section of Ultrasound at the Toronto General Hospital, University Health Network from 1984 until her departure in mid 2007, when she returned to her home in Alberta. She is now Clinical Professor of Radiology at the University of Calgary and a member of the Diagnostic Imaging Department at the Foothills Medical Centre. She has a cross appointment in the Department of Gastroenterology. Dr Wilson has invested her research, academic and practice pursuits on imaging of the gastrointestinal tract, pancreas and liver. From 1992 until 2007, Dr Wilson collaborated with Dr. Peter Burns from University of Toronto/Medical Imaging Research on the investigation of microbubble contrast agents for the evaluation of their use in Medical Imaging. Their major accomplishments to date include their investigation of the imaging and diagnosis of tumors of the liver. Burns and Wilson shared a grant (begun in the early nineties and successful for three renewals) from the Canadian Institute for Health Research (CHIR) for these investigations.
Apart from her research pursuits, Dr. Wilson has been the recipient of many prestigious awards, including the prestigious 2011 Jean A Vezina award for Excellence and Innovation in Radiology from the Société canadienne-française de radiologie (SCFR) and is the 2012 recipient of the Joseph Holmes Pioneer Award from the AIUM and the 2012 recipient of the Lifetime Achievement Award from the Society of Radiologists in Ultrasound(SRU).
Dr. Wilson is co-editor of the bell weather two-volume reference text book entitled Diagnostic Ultrasound, now in its fourth printing since 1992, published by Elsevier Science www.elsevier.com This very successful text book has served and continues to serve as a world wide reference for Ultrasound practitioners globally over the two decades.
Dr. Wilson was named the first, and the only, woman President of the Canadian Association of Radiologists in 1993 and was later awarded with the Canadian Association of Radiologists Gold Medal in 2001 for her contributions to Canadian Radiology. She has written over 150 peer reviewed publications and has presented over 400 international presentations. She is an active member of the Radiological Society of North America, the Canadian Association of Radiology, and the Society of Radiologists in Ultrasound. She is co-president of the International Contrast Ultrasound Society (ICUS).
Dr. Wilson runs one of the most advanced and well-known clinical and research facilities for the investigation of microbubble contrast agents for medical imaging in North America, recognized for its accomplishments throughout the world. She is also a recognized expert in the evaluation of inflammatory bowel disease with sonography. The advancement and choice of ultrasound for imaging of IBD is a major lifetime passion as is the use CEUS for the diagnosis and management of HCC."
Dr. Stephen Congly is a Clinical Assistant Professor at the University of Calgary with a practice consisting of both general and transplant hepatology. He is certified by the American Board of Internal Medicine in Internal Medicine, Gastroenterology and Transplant Hepatology and is a Fellow of the American College of Physicians.
He has a Masters of Science in Health Economics, Policy and Management from the London School of Economics and is a member of the O'Brien Institute for Public Health at the University of Calgary. His interests include health technology assessment, resource utilization, hepatocellular carcinoma, liver transplantation and sexual function in liver disease.
Stine Bordier Hoj
Stine completed a PhD in Spatial Epidemiology at the University of South Australia in 2016, under the supervision of Professor Mark Daniel and Dr Catherine Paquet. Her research interests center broadly upon understanding how structural and environmental forces shape human behaviour, opportunity, and health, and in employing innovative methods in research design and statistical analysis to answer these questions. Her PhD research capitalised on a longitudinal psychiatric epidemiological catchment area study in Montreal, Canada, to investigate associations between the level of tree cover in residential public open spaces and individual trajectories of wellbeing across a four-year period. Under the supervision of Dr Julie Bruneau at the University of Montreal, Stine is now working to build a new cohort of injecting drug users at risk of, or infected with, hepatitis C virus (HCV). This study will employ linkage to administrative databases as a means of 'virtual' follow-up in order to document the HCV cascade of care in this relatively hidden population.
Dr. Susan Gilmour, associate professor, Division of Pediatric Gastroenterology and Nutrition was appointed to the position of chair, department of pediatrics, University of Alberta and regional program clinical director for the Stollery Children’s Hospital in July 2009. She is also the director for the pediatric liver transplant program at the Stollery Children’s Hospital within Alberta Health Services.
William WL Wong
Dr. Wong is an assistant professor at the University of Waterloo School of Pharmacy. Hisresearch focuses on system-level policy modeling, infectious diseases modeling, health services and outcomes research, particularly in hepatitis B and C. His health services and outcomes research interests include quality of life research, costing and return on investment.